These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 34267469)

  • 1. Myeloablative Versus Reduced Intensity Conditioning Regimens for Allogeneic Hematopoietic Stem Cell Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Retrospective Analysis.
    Sharma SK; Choudhary D; Doval D; Khandelwal V; Patel A; Setia R; Dadu T; Handoo A
    Indian J Hematol Blood Transfus; 2021 Jul; 37(3):472-478. PubMed ID: 34267469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Myeloablative Versus Reduced-Intensity Conditioning Regimens for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia: A Cohort Study.
    Çiftçiler R; Göker H; Demiroğlu H; Aladağ E; Aksu S; Haznedaroğlu İC; Sayınalp N; Özcebe O; Tekin F; Büyükaşık Y
    Turk J Haematol; 2019 May; 36(2):88-96. PubMed ID: 30717586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience.
    Goker H; Ozdemir E; Uz B; Buyukasik Y; Turgut M; Serefhanoglu S; Aksu S; Sayinalp N; Haznedaroglu IC; Tekin F; Karacan Y; Unal S; Eliacik E; Isik A; Ozcebe OI
    Transfus Apher Sci; 2013 Dec; 49(3):590-9. PubMed ID: 23981652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myeloablative versus Reduced-Intensity Conditioning in Patients with Myeloid Malignancies: A Propensity Score-Matched Analysis.
    Sibai H; Falcone U; Deotare U; Michelis FV; Uhm J; Gupta V; Kuruvilla J; Lipton JH; Seftel MD; Messner HA; Kim DDH
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2270-2275. PubMed ID: 27596129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
    Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.
    Gooptu M; Kim HT; Ho VT; Alyea EP; Koreth J; Armand P; Ritz J; Nikiforow S; Glotzbecker BE; Nageshwar P; Soiffer RJ; Antin JH; Cutler CS
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1733-1740. PubMed ID: 29555313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT.
    Shimoni A; Robin M; Iacobelli S; Beelen D; Mufti GJ; Ciceri F; Bethge W; Volin L; Blaise D; Ganser A; Luft T; Chevallier P; Schwerdtfeger R; Koster L; de Witte T; Kröger N; Nagler A; Yakoub-Agha I
    Br J Haematol; 2021 Nov; 195(3):417-428. PubMed ID: 34514596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT.
    Rubio MT; Savani BN; Labopin M; Piemontese S; Polge E; Ciceri F; Bacigalupo A; Arcese W; Koc Y; Beelen D; Gülbas Z; Wu D; Santarone S; Tischer J; Afanasyev B; Schmid C; Giebel S; Mohty M; Nagler A
    J Hematol Oncol; 2016 Mar; 9():25. PubMed ID: 26980295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced Intensity Conditioning Followed by Allogeneic Hematopoietic Stem Cell Transplantation Is a Good Choice for Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Meta-Analysis of Randomized Controlled Trials.
    Song Y; Yin Z; Ding J; Wu T
    Front Oncol; 2021; 11():708727. PubMed ID: 34692485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis.
    Murthy GSG; Kim S; Estrada-Merly N; Abid MB; Aljurf M; Assal A; Badar T; Badawy SM; Ballen K; Beitinjaneh A; Cerny J; Chhabra S; DeFilipp Z; Dholaria B; Perez MAD; Farhan S; Freytes CO; Gale RP; Ganguly S; Gupta V; Grunwald MR; Hamad N; Hildebrandt GC; Inamoto Y; Jain T; Jamy O; Juckett M; Kalaycio M; Krem MM; Lazarus HM; Litzow M; Munker R; Murthy HS; Nathan S; Nishihori T; Ortí G; Patel SS; Van der Poel M; Rizzieri DA; Savani BN; Seo S; Solh M; Verdonck LF; Wirk B; Yared JA; Nakamura R; Oran B; Scott B; Saber W
    Haematologica; 2023 Jul; 108(7):1900-1908. PubMed ID: 36779595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Myeloablative versus Reduced-Intensity Conditioning Regimens in Allogeneic Stem Cell Transplantation Recipients with Acute Myelogenous Leukemia with Measurable Residual Disease-Negative Disease at the Time of Transplantation: A Retrospective Cohort Study.
    Yu J; Du Y; Ahmad S; Patel RD; Varela JC; Chang CC; Mori S
    Transplant Cell Ther; 2021 Aug; 27(8):663.e1-663.e6. PubMed ID: 33951497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.
    Le Bourgeois A; Mohr C; Guillaume T; Delaunay J; Malard F; Loirat M; Peterlin P; Blin N; Dubruille V; Mahe B; Gastinne T; Le Gouill S; Moreau P; Mohty M; Planche L; Lode L; Bene MC; Chevallier P
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):934-9. PubMed ID: 23523970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial.
    Scott BL; Pasquini MC; Fei M; Fraser R; Wu J; Devine SM; Porter DL; Maziarz RT; Warlick E; Fernandez HF; Soiffer RJ; Alyea E; Hamadani M; Bashey A; Giralt S; Geller NL; Leifer E; Hourigan CS; Gui G; Mendizabal A; Horowitz MM; Deeg HJ; Horwitz ME
    Transplant Cell Ther; 2021 Jun; 27(6):483.e1-483.e6. PubMed ID: 33775615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced-intensity and myeloablative conditioning allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and myelodysplastic syndrome: a meta-analysis and systematic review.
    Zeng W; Huang L; Meng F; Liu Z; Zhou J; Sun H
    Int J Clin Exp Med; 2014; 7(11):4357-68. PubMed ID: 25550955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS.
    Alatrash G; Kidwell KM; Thall PF; Di Stasi A; Chen J; Zope M; Crain AK; Champlin RE; Popat U; Shpall EJ; Jones RB; Andersson BS
    Bone Marrow Transplant; 2019 Aug; 54(8):1245-1253. PubMed ID: 30532055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation.
    Shimoni A; Labopin M; Savani B; Volin L; Ehninger G; Kuball J; Bunjes D; Schaap N; Vigouroux S; Bacigalupo A; Veelken H; Sierra J; Eder M; Niederwieser D; Mohty M; Nagler A
    J Hematol Oncol; 2016 Nov; 9(1):118. PubMed ID: 27821187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effectiveness of busulfan/cyclophosphamide versus busulfan/fludarabine myeloablative conditioning for allogeneic hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome.
    Patel SS; Rybicki L; Pohlman B; Bolwell B; Gerds AT; Hamilton BK; Hanna R; Kalaycio M; Majhail NS; Sobecks R
    Hematol Oncol Stem Cell Ther; 2020 Sep; 13(3):160-165. PubMed ID: 31628924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced-intensity versus Myeloablative Conditioning Regimens for Younger Adults with Acute Myeloid Leukemia and Myelodysplastic Syndrome: A systematic review and meta-analysis.
    Ma S; Shi W; Li Z; Tang L; Wang H; Xia L; Hu Y
    J Cancer; 2020; 11(17):5223-5235. PubMed ID: 32742468
    [No Abstract]   [Full Text] [Related]  

  • 19. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.
    Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A
    Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Less Is More: Superior Graft-versus-Host Disease-Free/Relapse-Free Survival with Reduced-Intensity Conditioning and Dual T Cell Depletion in Acute Myelogenous Leukemia.
    Salas MQ; Chen S; Lam W; Pasic I; Gerbitz A; Michelis FV; Kim DDH; Al-Shaibani Z; Lipton JH; Mattsson J; Kumar R; Viswabandya A; Law AD
    Biol Blood Marrow Transplant; 2020 Aug; 26(8):1511-1519. PubMed ID: 32422253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.